Chris Barrett
Corporate Officer/Principal presso BIOHAVEN LTD.
Provenienza dei contatti di primo grado di Chris Barrett
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 25 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Chris Barrett tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director of Finance/CFO Director/Board Member Director/Board Member Compliance Officer Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member Director of Finance/CFO Investor Relations Contact | |
| University of Connecticut | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree Undergraduate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Yale University | College/University | Undergraduate Degree Undergraduate Degree | |
Veradermics, Inc.
 Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Undergraduate Degree | |
| Georgetown University | College/University | Graduate Degree Undergraduate Degree | |
Portage Pharmaceutical Ltd.
 Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Miscellaneous Commercial Services | Chairman Chief Operating Officer | |
Pyramid Biosciences, Inc.
 Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| Yale School of Medicine | College/University | Corporate Officer/Principal Undergraduate Degree | |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Pharmaceuticals: Major | Founder | |
| South Dakota State University | College/University | Undergraduate Degree | |
K36 Therapeutics, Inc.
 K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Pharmaceuticals: Major | Director/Board Member | |
Adnexus
 Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| SYNLOGIC, INC. | Biotechnology | Director/Board Member | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Chairman | |
| The Creighton University School of Medicine | College/University | Graduate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Corporate Officer/Principal | |
University of Washington Medical Center
 University of Washington Medical Center Other Consumer ServicesConsumer Services University of Washington Medical Center provides healthcare services. It offers gynecology, bariatric, obstetrics, radiology, rehabilitation, neurology, gastric, otolaryngology, ankle, radiology and imaging services. The company was founded on March 1, 1945 and is headquartered in Seattle, WA | College/University | Corporate Officer/Principal | |
| The Danish American Chamber of Commerce | Director/Board Member | ||
| New York University School of Medicine | College/University | Graduate Degree | |
Adage Capital Management LP
 Adage Capital Management LP Investment ManagersFinance Adage Capital Management LP (Adage) is a SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Phil Gross and Robert Atchinson in 2001 and is owned by Adage Capital Partners GP LLC. Adage provides investment advisory services to its sole client, Adage Capital Partners LP (ACP), a private investment fund. The firm does not manage any separate accounts. | Investment Managers | Analyst-Equity | |
| EVERCORE INC. | Investment Banks/Brokers | Corporate Officer/Principal | |
| New York University | College/University | Undergraduate Degree | |
Surveyor Capital Ltd.
 Surveyor Capital Ltd. Investment ManagersFinance Surveyor Capital Ltd. is a hedge fund seeding platform headquartered in New York City. The firm was founded in 2008 and is a subsidiary of Citadel LP, which is owned by GFH HFEVA LLC. Surveyor Capital manages capital exclusively for Citadel’s multi-strategy funds and its positions are consolidated in Form 13F filed by Citadel Advisors LLC. | Investment Managers | Portfolio Manager-Equities | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Chairman | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member | |
Indalo Therapeutics, Inc.
 Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
| COLLEGIUM PHARMACEUTICAL, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Financial Conglomerates | Founder | |
| MANX FINANCIAL GROUP PLC | Regional Banks | Director/Board Member | |
Viscogliosi Brothers LLC
 Viscogliosi Brothers LLC Investment ManagersFinance Viscogliosi Brothers LLC is a venture capital, private equity and merchant banking firm which was founded in 1999 by Marc Viscogliosi, John Viscogliosi and Anthony Viscogliosi. The firm headquartered in New York. | Investment Managers | Corporate Officer/Principal | |
Chelsea Avondale Ltd.
 Chelsea Avondale Ltd. Property/Casualty InsuranceFinance Chelsea Avondale Ltd. has developed Skynet, a precision risk technology for property and casualty insurance. The company is based in Hamilton, Bermuda and has subsidiaries in Barbados. Skynet was created by going back to the scientific principles that cause insurance claims. The first implementation of Skynet was completed in Chelsea Avondale's wholly owned Bermudian insurance company, Max Insurance. Chelsea Avondale believes that scientific underwriting is the future of insurance. The company was founded by Gregory H. Bailey and the CEO is Nilesh Mukundrai G. Vasani. | Property/Casualty Insurance | Founder | |
Propel LLC (Iowa)
 Propel LLC (Iowa) Packaged SoftwareTechnology Services Propel LLC is a private company based in Des Moines, IA and has subsidiaries in the United States. Propel LLC offers fractional executive services with executive-level marketing. The company's fractional executives are experienced and have worked with top corporate brands and successful start-ups. Propel LLC provides diverse and proven subscription-based fractional executives to take businesses to new heights. The company offers fractional chief operating officer solutions to its leading network of fractional chief marketing officers. Propel LLC's rebrand reflects its tagline and motto: move forward today. The company was founded by Gregory H. Bailey, who has been the CEO since incorporation. | Packaged Software | Chief Executive Officer | |
Serina Therapeutics, Inc.
 Serina Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Serina Therapeutics, Inc. is a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley in 2006 and is headquartered in Huntsville, AL. | Miscellaneous Commercial Services | Director/Board Member | |
TYRX, Inc.
 TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Equipment/Instruments | Director/Board Member | |
| AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
| CORNERSTONE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 43 |
| Regno Unito | 3 |
| Canada | 2 |
| Danimarca | 2 |
| Bermuda | 2 |
Settori
| Health Technology | 19 |
| Finance | 14 |
| Consumer Services | 12 |
| Commercial Services | 4 |
| Technology Services | 2 |
Posizioni
| Director/Board Member | 127 |
| Corporate Officer/Principal | 60 |
| Independent Dir/Board Member | 35 |
| Chairman | 30 |
| Founder | 26 |
Contatti più connessi
| Insiders | |
|---|---|
| John Childs | 40 |
| Gregory Bailey | 36 |
| Robert Hugin | 24 |
| Michael Heffernan | 23 |
| Julia Gregory | 22 |
| Irina Antonijevic | 17 |
| Kishan Mehta | 15 |
| Vladimir Coric | 14 |
| Matthew Buten | 13 |
| Warren Volles | 6 |
| Kimberly Gentile | 6 |
| Douglas G. Gray | 6 |
| Megan M. Dow | 6 |
| Clifford Bechtold | 6 |
| Jennifer Porcelli | 5 |
- Borsa valori
- Insiders
- Chris Barrett
- Connessioni Società
